Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT
about
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United StatesNon-M variants of human immunodeficiency virus type 1.Longitudinal quasispecies analysis of viral variants in HIV type 1 dually infected individuals highlights the importance of sequence identity in viral recombination.Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasmaInfection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virusCross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.Correlation of immune activation with HIV-1 RNA levels assayed by real-time RT-PCR in HIV-1 subtype C infected patients in Northern India.Comparative evaluation of the performance of the Abbott RealTime HIV-1 assay for measurement of HIV-1 plasma viral load on genetically diverse samples from GreeceUse of quantitative HIV RNA detection for early diagnosis of HIV infection in infants and acute HIV infections in Alberta, CanadaCurrent practices in laboratory monitoring of HIV infection.A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection.Cross-subtype detection of HIV-1 using reverse transcription and recombinase polymerase amplificationPerspectives on introduction and implementation of new point-of-care diagnostic testsRates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in BrazilCRF22_01A1 is involved in the emergence of new HIV-1 recombinants in Cameroon.Single real-time reverse transcription-PCR assay for detection and quantification of genetically diverse HIV-1, SIVcpz, and SIVgor strains.Frequency, causes, and new challenges of indeterminate results in Western blot confirmatory testing for antibodies to human immunodeficiency virus.Molecular assays for monitoring HIV infection and antiretroviral therapy.Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENEvaluation of the Abbott m2000rt RealTime HIV-1 assay with manual sample preparation compared with the ROCHE COBAS AmpliPrep/AMPLICOR HIV-1 MONITOR v1.5 using specimens from East Africa.Evaluation of the Upgraded Version 2.0 of the Roche COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Qualitative Assay in Central African Children.Current challenges to viral load testing in the context of emerging genetic diversity of HIV-1.Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma.Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.Early infant diagnosis of HIV-1 infection in Luanda, Angola, using a new DNA PCR assay and dried blood spots.Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay.HIV-1 load comparison using four commercial real-time assaysThermodynamically modulated partially double-stranded linear DNA probe design for homogeneous real-time PCRComparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation.Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests.Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction.A cluster of human immunodeficiency virus Type 1 recombinant form escaping detection by commercial genomic amplification assays.Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine.Towards an early diagnosis of HIV infection: an electrochemical approach for detection of HIV-1 reverse transcriptase enzyme.
P2860
Q28675438-949AF177-4E4D-4DAD-AD2E-14939A5A2311Q30432689-78BD4670-8C8E-4D2C-AAAF-067FD0AD8126Q33827794-717ABCDC-1646-446D-A0FE-1F658710545DQ34089637-71982F54-537F-4013-AE04-9E4FCE66FA8FQ34120140-3953521E-94BD-41B3-9D4E-CF698C839DE5Q34301929-907E0592-6A13-4D90-9810-F81990510E2BQ34505991-F814A0C4-4381-42E7-9A48-1D4C1789E8E0Q34547246-1154E438-D898-4D7A-81A9-79AD83B9B846Q35689008-35CAEF78-D2F1-443D-901A-757CE3D66430Q35770853-E6227722-A7A1-415A-8726-3FF1D9EE3ECDQ35807096-5D587729-01B3-4063-B086-BE6FB11CBBD2Q35907285-10EFE6E1-4A8A-4777-A88E-51CDCC9CE612Q35907400-3097C1D3-4446-48A3-BC63-7631BAD507ECQ35913979-AAB27B31-F04E-482A-853A-9FBC1909F29BQ36084257-06D67340-7940-4F2C-BC93-2F44E4565DA2Q36667567-DEFE7961-711D-4526-908D-66336164C934Q36780418-A6E77591-5EAB-46D3-BA40-63090D72F708Q36816024-5BBF5D35-7106-4A62-908F-149C67642DE7Q37206232-CDE9C134-B292-4681-9DD4-4FE996AF7A07Q37256264-19B9B2D2-0A9B-4EB7-9E01-318C5F0898F0Q37386429-FF70916C-C009-4A42-AFFD-5AAA224C0759Q37387517-03A3B00B-933C-428D-90D8-655D70423E49Q38088726-971E4744-2497-4873-A2E6-1B53DDDD201DQ38473488-62CF6032-5EBD-4C50-9E1F-D7C138DC19F0Q38871741-E7994CB8-3F96-4954-8FC8-4A3164BF16EEQ40120069-8157BD4B-8343-4547-8BF3-6E21A26431A6Q41505058-E1E68329-F82D-46EE-A60E-9F3A294CA69EQ42030505-4C40BAE2-97F5-42DB-B84E-97C9637CB720Q42113208-85B574A6-E619-4638-8593-9C0221E87450Q42160975-4BC71D73-F4F1-4DFD-9FFE-E729D3DBF4A3Q42408684-8B68138C-AEC3-4B2F-B2CE-2C492EB33D44Q43146501-3B5FCBA4-05BC-4982-B27A-FF49EDCE81E9Q44913678-FB37E264-6374-4CFE-86D0-210D48F46F1AQ45371172-DEB1C0E0-C5A6-4F3B-8598-D23676042764Q51081557-CF8AC3CE-E7CA-471F-899B-65A3050AE83DQ54629218-6336DFC3-C468-4D99-A311-57AA5B41FE65
P2860
Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@en
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@nl
type
label
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@en
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@nl
prefLabel
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@en
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@nl
P2093
P2860
P1476
Impact of human immunodeficien ...... NA 3.0, and NucliSens HIV-1 QT
@en
P2093
Alan Golden
Carmen de Mendoza
John Hackett
Priscilla Swanson
Richard L Hodinka
Sushil G Devare
Yagnya Joshi
P2860
P304
P356
10.1128/JCM.43.8.3860-3868.2005
P407
P577
2005-08-01T00:00:00Z